Farther Finance Advisors LLC Acquires 13,372 Shares of Bristol-Myers Squibb (NYSE:BMY)

Farther Finance Advisors LLC lifted its stake in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 59.3% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 35,912 shares of the biopharmaceutical company's stock after buying an additional 13,372 shares during the period. Farther Finance Advisors LLC's holdings in Bristol-Myers Squibb were worth $2,139,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in BMY. LaFleur & Godfrey LLC lifted its holdings in shares of Bristol-Myers Squibb by 3.5% during the 4th quarter. LaFleur & Godfrey LLC now owns 43,551 shares of the biopharmaceutical company's stock worth $2,463,000 after acquiring an additional 1,487 shares during the period. Brighton Jones LLC raised its position in Bristol-Myers Squibb by 33.4% during the fourth quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company's stock valued at $1,116,000 after purchasing an additional 4,935 shares in the last quarter. Newbridge Financial Services Group Inc. bought a new stake in Bristol-Myers Squibb during the fourth quarter worth $57,000. Savant Capital LLC increased its stake in shares of Bristol-Myers Squibb by 1.3% in the 4th quarter. Savant Capital LLC now owns 96,631 shares of the biopharmaceutical company's stock valued at $5,465,000 after purchasing an additional 1,231 shares during the last quarter. Finally, Comprehensive Financial Planning Inc. PA acquired a new position in shares of Bristol-Myers Squibb during the 4th quarter worth $34,000. Institutional investors and hedge funds own 76.41% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on BMY. Piper Sandler started coverage on Bristol-Myers Squibb in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $65.00 target price on the stock. Jefferies Financial Group lowered their price objective on shares of Bristol-Myers Squibb from $70.00 to $68.00 and set a "buy" rating for the company in a research report on Wednesday, April 23rd. The Goldman Sachs Group restated a "neutral" rating and issued a $55.00 target price (down previously from $67.00) on shares of Bristol-Myers Squibb in a research report on Tuesday, April 8th. Argus upgraded shares of Bristol-Myers Squibb to a "hold" rating in a report on Friday, April 25th. Finally, Cantor Fitzgerald restated a "neutral" rating and set a $55.00 price objective on shares of Bristol-Myers Squibb in a research report on Tuesday, April 22nd. Two analysts have rated the stock with a sell rating, thirteen have given a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $58.00.

Insider Buying and Selling at Bristol-Myers Squibb

In other news, EVP Samit Hirawat bought 4,250 shares of Bristol-Myers Squibb stock in a transaction dated Friday, April 25th. The stock was bought at an average cost of $47.58 per share, for a total transaction of $202,215.00. Following the purchase, the executive vice president now directly owns 83,513 shares in the company, valued at approximately $3,973,548.54. This represents a 5.36% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.09% of the company's stock.

Bristol-Myers Squibb Trading Down 1.9%

Shares of BMY stock traded down $0.99 during mid-day trading on Friday, hitting $49.71. The company's stock had a trading volume of 9,394,854 shares, compared to its average volume of 12,995,538. Bristol-Myers Squibb has a 52 week low of $39.35 and a 52 week high of $63.33. The company has a debt-to-equity ratio of 2.90, a quick ratio of 1.15 and a current ratio of 1.25. The company's fifty day simple moving average is $48.71 and its 200-day simple moving average is $54.77. The company has a market cap of $101.15 billion, a PE ratio of -11.25, a P/E/G ratio of 2.07 and a beta of 0.38.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.50 by $0.30. The firm had revenue of $11.20 billion for the quarter, compared to analysts' expectations of $10.77 billion. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. The company's revenue for the quarter was down 5.6% compared to the same quarter last year. During the same period in the prior year, the business earned ($4.40) EPS. As a group, equities research analysts expect that Bristol-Myers Squibb will post 6.74 earnings per share for the current fiscal year.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.